Loading
HKSEHealthcareBiotechnology
Latest quote
HK$43.16
+HK$1.58 · +3.80%
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trials, registration and declaration of clinical trials, on-site services, as well as data management and analysis, etc. The company was founded on December 15, 2004 and is headquartered in Hangzhou, China.
Latest quote
HK$43.16
+HK$1.58 · +3.80%
Regular session · HKT · Market data may be delayed.
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trials, registration and declaration of clinical trials, on-site services, as well as data management and analysis, etc. The company was founded on December 15, 2004 and is headquartered in Hangzhou, China.
Day range
Current HK$43.16
52-week range
Current HK$43.16
Regular session · HKT · Market data may be delayed.
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trials, registration and declaration of clinical trials, on-site services, as well as data management and analysis, etc. The company was founded on December 15, 2004 and is headquartered in Hangzhou, China.
Day range
Current HK$43.16
52-week range
Current HK$43.16
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.83B CNY | 6.6B CNY | 7.38B CNY | 7.09B CNY | 5.21B CNY |
| Cost of goods sold | 4.96B CNY | 4.36B CNY | 4.54B CNY | 4.28B CNY | 2.94B CNY |
| Gross profit | 1.87B CNY | 2.24B CNY | 2.85B CNY | 2.81B CNY | 2.27B CNY |
| Research and development | 257.64M CNY | 238.39M CNY | 261.56M CNY | 234.62M CNY | 211.83M CNY |
| Selling, general, and administrative | 322.2M CNY | 349.25M CNY | 306.72M CNY | 405.95M CNY | 373.42M CNY |
| Operating expenses | 863.77M CNY | 1.58B CNY | 361.59M CNY | 997.69M CNY | 892.77M CNY |
| Interest income | 15.13M CNY | 90.22M CNY | 229.85M CNY | 227.34M CNY | 255.88M CNY |
| Interest expense | 90.56M CNY | 141.24M CNY | 119.9M CNY | 83.18M CNY | 24.91M CNY |
| Depreciation and amortization | 326.67M CNY | 324.14M CNY | 305.69M CNY | 264.75M CNY | 188.92M CNY |
| Operating income | 1.01B CNY | 664.42M CNY | 2.49B CNY | 2.58B CNY | 1.92B CNY |
| Net income | 887.89M CNY | 405.14M CNY | 2.02B CNY | 2.01B CNY | 2.87B CNY |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
HK$0.3245
2025 complete year-10.3% since 2021
2026 partial: HK$0.1447
HK$0.3619
2,021
HK$0.5796
2,022
HK$0.6156
2,023
HK$0.6237
2,024
HK$0.3245
2,025
HK$0.1447
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 18, 2026 | HK$0.1447Annual | Jun 22, 2026 | Jul 22, 2026 |
Dividend | Jun 12, 2025 | HK$0.3245Annual | Jun 13, 2025 | Jul 11, 2025 |
Dividend | Jun 7, 2024 | HK$0.6237Annual | Jun 11, 2024 | Jul 18, 2024 |
Dividend | May 25, 2023 | HK$0.6156Annual | May 29, 2023 | Jul 7, 2023 |
Dividend | May 24, 2022 | HK$0.5796Annual | May 25, 2022 | Jun 20, 2022 |
Dividend | May 25, 2021 | HK$0.3619Annual | May 26, 2021 | Jun 21, 2021 |
Ex-dividend Jun 18, 2026
HK$0.1447
Annual
Record Jun 22, 2026 · Payment Jul 22, 2026
Ex-dividend Jun 12, 2025
HK$0.3245
Annual
Record Jun 13, 2025 · Payment Jul 11, 2025
Ex-dividend Jun 7, 2024
HK$0.6237
Annual
Record Jun 11, 2024 · Payment Jul 18, 2024
Ex-dividend May 25, 2023
HK$0.6156
Annual
Record May 29, 2023 · Payment Jul 7, 2023
Ex-dividend May 24, 2022
HK$0.5796
Annual
Record May 25, 2022 · Payment Jun 20, 2022
Ex-dividend May 25, 2021
HK$0.3619
Annual
Record May 26, 2021 · Payment Jun 21, 2021
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard FTSE Emerging Markets ETFVWO8.75M0.01%162.3B USD0.06%$61.23-0.34%
Vanguard Total International Stock ETFVXUS8.53M0.00%646.2B USD0.05%$88.08-0.37%
Vanguard FTSE All-World ex-US ETFVEU1.32M0.00%95.9B USD0.04%$86.06-0.41%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM776.29K0.01%9.76B USD0.39%$40.94-0.15%
Schwab Emerging Markets Equity ETFSCHE730.72K0.01%13.14B USD0.06%$37.49-0.24%
JPMorgan ActiveBuilders Emerging Markets Equity ETFJEMA609.07K0.03%1.8B USD0.33%$63.79+0.08%
Vanguard Total World Stock ETFVT406.94K0.00%97.9B USD0.06%$160.92-0.50%
Dimensional - Emerging Core Equity Market ETFDFAE391.86K0.00%10.29B USD0.29%$40.58+0.02%Vanguard FTSE Emerging Markets ETFVWOVanguard Total International Stock ETFVXUSVanguard FTSE All-World ex-US ETFVEUDimensional - Emerging Markets Core Equity 2 ETFDFEMSchwab Emerging Markets Equity ETFSCHEJPMorgan ActiveBuilders Emerging Markets Equity ETFJEMAVanguard Total World Stock ETFVTDimensional - Emerging Core Equity Market ETFDFAEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
